AVDL vs SUPN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AVDL Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avadel Pharmaceuticals plc Ordinary Share (AVDL) driven by superior Valuation, Momentum & Technical, Options & Structure while SUPN counters with relative strength in Growth & Margin. Fundamentally, AVDL trades at 28.8x Forward P/E with 2.5% operating margin (+54.9% YoY revenue) versus SUPN at 7.2x Forward P/E and 46.9% operating margin (+13.4% YoY). In options structure, AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against SUPN sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AVDL | SUPN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.1B | $5.9B | Larger Scale | SUPN |
| Trailing P/E Ratio Valuation | 16.8x | 20.2x | Lower Multiple | AVDL |
| Forward P/E Ratio Valuation | 28.8x | 7.2x | Lower Multiple | SUPN |
| Revenue Growth (YoY) Growth | +54.9% | +13.4% | Higher Growth | AVDL |
| Operating Margin (TTM) Profitability | 2.5% | 46.9% | Higher Margin | SUPN |
| Net Profit Margin Profitability | -0.1% | 32.8% | Higher Margin | SUPN |
| Return on Equity (ROE) Capital Efficiency | -0.3% | -4.2% | Higher ROE | AVDL |
| 52-Week Range Position Momentum | 89% ($6โ$24) | 8% ($26โ$60) | Stronger Trend | AVDL |
| Beta / 30D Volatility Risk Regime | 0.14ฮฒ ยท 2% Vol | 0.64ฮฒ ยท 120% Vol | Lower Realized Risk | AVDL |
| Unified Institutional Score Composite Signal | 62.9 / 100 (BUY) | 54.3 / 100 (HOLD) | Higher Composite | AVDL |